Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of AimovigŪ (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

Friday, May 3, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store